A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

Tinnakorn Chaiworapongsa; Roberto Romero; Adi L. Tarca; Juan Pedro Kusanovic; Francesca Gotsch; Pooja Mittal; Sun Kwon Kim; Edi Vaisbuch; Shali Mazaki-Tovi; Offer Erez; Zhong Dong; Chong Jai Kim; Lami Yeo; Sonia S. Hassan

doi:10.1016/j.ajog.2010.04.002

A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

Tinnakorn Chaiworapongsa^*
, Roberto Romero
, Adi L. Tarca
, Juan Pedro Kusanovic
, Francesca Gotsch
, Pooja Mittal
, Sun Kwon Kim
, Edi Vaisbuch
, Shali Mazaki-Tovi
, Offer Erez
, Zhong Dong
, Chong Jai Kim
, Lami Yeo
, Sonia S. Hassan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Objective: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. Study Design: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. Results: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001). Conclusion: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm.

Original language	English
Pages (from-to)	550.e1-550.e10
Journal	American Journal of Obstetrics and Gynecology
Volume	202
Issue number	6
DOIs	https://doi.org/10.1016/j.ajog.2010.04.002
State	Published - Jun 2010
Externally published	Yes

Keywords

angiogenesis
biomarker
longitudinal study
mechanisms of disease
pregnancy-induced hypertension

Access to Document

10.1016/j.ajog.2010.04.002

Cite this

Chaiworapongsa, T., Romero, R., Tarca, A. L., Kusanovic, J. P., Gotsch, F., Mittal, P., Kim, S. K., Vaisbuch, E., Mazaki-Tovi, S., Erez, O., Dong, Z., Kim, C. J., Yeo, L., & Hassan, S. S. (2010). A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 202(6), 550.e1-550.e10. https://doi.org/10.1016/j.ajog.2010.04.002

@article{850ac39287a641a2864b21564896b9f2,

title = "A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia",

abstract = "Objective: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. Study Design: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. Results: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001). Conclusion: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm.",

keywords = "angiogenesis, biomarker, longitudinal study, mechanisms of disease, pregnancy-induced hypertension",

author = "Tinnakorn Chaiworapongsa and Roberto Romero and Tarca, \{Adi L.\} and Kusanovic, \{Juan Pedro\} and Francesca Gotsch and Pooja Mittal and Kim, \{Sun Kwon\} and Edi Vaisbuch and Shali Mazaki-Tovi and Offer Erez and Zhong Dong and Kim, \{Chong Jai\} and Lami Yeo and Hassan, \{Sonia S.\}",

year = "2010",

month = jun,

doi = "10.1016/j.ajog.2010.04.002",

language = "אנגלית",

volume = "202",

pages = "550.e1--550.e10",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Elsevier Inc.",

number = "6",

}

Chaiworapongsa, T, Romero, R, Tarca, AL, Kusanovic, JP, Gotsch, F, Mittal, P, Kim, SK, Vaisbuch, E, Mazaki-Tovi, S, Erez, O, Dong, Z, Kim, CJ, Yeo, L & Hassan, SS 2010, 'A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia', American Journal of Obstetrics and Gynecology, vol. 202, no. 6, pp. 550.e1-550.e10. https://doi.org/10.1016/j.ajog.2010.04.002

TY - JOUR

T1 - A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

AU - Chaiworapongsa, Tinnakorn

AU - Romero, Roberto

AU - Tarca, Adi L.

AU - Kusanovic, Juan Pedro

AU - Gotsch, Francesca

AU - Mittal, Pooja

AU - Kim, Sun Kwon

AU - Vaisbuch, Edi

AU - Mazaki-Tovi, Shali

AU - Erez, Offer

AU - Dong, Zhong

AU - Kim, Chong Jai

AU - Yeo, Lami

AU - Hassan, Sonia S.

PY - 2010/6

Y1 - 2010/6

N2 - Objective: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. Study Design: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. Results: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001). Conclusion: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm.

AB - Objective: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. Study Design: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. Results: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001). Conclusion: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm.

KW - angiogenesis

KW - biomarker

KW - longitudinal study

KW - mechanisms of disease

KW - pregnancy-induced hypertension

UR - https://www.scopus.com/pages/publications/77952863949

U2 - 10.1016/j.ajog.2010.04.002

DO - 10.1016/j.ajog.2010.04.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20510958

AN - SCOPUS:77952863949

SN - 0002-9378

VL - 202

SP - 550.e1-550.e10

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 6

ER -

A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this